Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 195

1.

Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovir + emtricitabine/lamivudine + efavirenz administered on a multiple tablet therapy.

Blanco JL, Montaner JS, Marconi VC, Santoro MM, Campos-Loza AE, Shafer RW, Miller MD, Paredes R, Harrigan R, Nguyen ML, Perno CF, Gonzalez-Hernandez LA, Gatell JM.

AIDS. 2014 Nov 13;28(17):2531-9. doi: 10.1097/QAD.0000000000000424.

PMID:
25574957
2.

Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors.

Basson AE, Rhee SY, Parry CM, El-Khatib Z, Charalambous S, De Oliveira T, Pillay D, Hoffmann C, Katzenstein D, Shafer RW, Morris L.

Antimicrob Agents Chemother. 2015 Feb;59(2):960-71. doi: 10.1128/AAC.04215-14. Epub 2014 Nov 24.

PMID:
25421485
3.

A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses.

Kolomeets AN, Varghese V, Lemey P, Bobkova MR, Shafer RW.

AIDS. 2014 Nov 13;28(17):F1-8. doi: 10.1097/QAD.0000000000000485.

PMID:
25259833
4.

Similar prevalence of low-abundance drug-resistant variants in treatment-naive patients with genotype 1a and 1b hepatitis C virus infections as determined by ultradeep pyrosequencing.

Margeridon-Thermet S, Le Pogam S, Li L, Liu TF, Shulman N, Shafer RW, Najera I.

PLoS One. 2014 Aug 20;9(8):e105569. doi: 10.1371/journal.pone.0105569. eCollection 2014.

5.

2014 Update of the drug resistance mutations in HIV-1.

Wensing AM, Calvez V, Günthard HF, Johnson VA, Paredes R, Pillay D, Shafer RW, Richman DD.

Top Antivir Med. 2014 Jun-Jul;22(3):642-50.

6.

Genome-wide association study of peripheral neuropathy with D-drug-containing regimens in AIDS Clinical Trials Group protocol 384.

Leger PD, Johnson DH, Robbins GK, Shafer RW, Clifford DB, Li J, McLaren PJ, Haas DW.

J Neurovirol. 2014 Jun;20(3):304-8. doi: 10.1007/s13365-014-0235-9. Epub 2014 Feb 20.

PMID:
24554482
7.

HIV-1 transmission networks in a small world.

Pennings PS, Holmes SP, Shafer RW.

J Infect Dis. 2014 Jan 15;209(2):180-2. doi: 10.1093/infdis/jit525. Epub 2013 Oct 22. No abstract available.

8.

Site nurse-initiated adherence and symptom support telephone calls for HIV-positive individuals starting antiretroviral therapy, ACTG 5031: substudy of ACTG 384.

Robbins GK, Testa MA, Su M, Safren SA, Morse G, Lammert S, Shafer RW, Reynolds NR, Chesney MA.

HIV Clin Trials. 2013 Sep-Oct;14(5):235-53. doi: 10.1310/hct1405-235.

9.

Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing.

Melikian GL, Rhee SY, Varghese V, Porter D, White K, Taylor J, Towner W, Troia P, Burack J, Dejesus E, Robbins GK, Razzeca K, Kagan R, Liu TF, Fessel WJ, Israelski D, Shafer RW.

J Antimicrob Chemother. 2014 Jan;69(1):12-20. doi: 10.1093/jac/dkt316. Epub 2013 Aug 9.

10.

Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens.

Van Zyl GU, Liu TF, Claassen M, Engelbrecht S, de Oliveira T, Preiser W, Wood NT, Travers S, Shafer RW.

PLoS One. 2013 Jun 26;8(6):e67188. Print 2013.

11.

Prototypical Recombinant Multi-Protease Inhibitor Resistant Infectious Molecular Clones of Human Immunodeficiency Virus Type-1.

Varghese V, Mitsuya Y, Fessel WJ, Liu TF, Melikian GL, Katzenstein DA, Schiffer CA, Holmes SP, Shafer RW.

Antimicrob Agents Chemother. 2013 Jun 24. [Epub ahead of print]

12.

Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine.

Tang MW, Rhee SY, Bertagnolio S, Ford N, Holmes S, Sigaloff KC, Hamers RL, de Wit TF, Fleury HJ, Kanki PJ, Ruxrungtham K, Hawkins CA, Wallis CL, Stevens W, van Zyl GU, Manosuthi W, Hosseinipour MC, Ngo-Giang-Huong N, Belec L, Peeters M, Aghokeng A, Bunupuradah T, Burda S, Cane P, Cappelli G, Charpentier C, Dagnra AY, Deshpande AK, El-Katib Z, Eshleman SH, Fokam J, Gody JC, Katzenstein D, Koyalta DD, Kumwenda JJ, Lallemant M, Lynen L, Marconi VC, Margot NA, Moussa S, Ndung'u T, Nyambi PN, Orrell C, Schapiro JM, Schuurman R, Sirivichayakul S, Smith D, Zolfo M, Jordan MR, Shafer RW.

J Infect Dis. 2013 Jun 15;207 Suppl 2:S70-7. doi: 10.1093/infdis/jit114.

13.

In vitro HIV-1 evolution in response to triple reverse transcriptase inhibitors & in silico phenotypic analysis.

Rath BA, Yousef KP, Katzenstein DK, Shafer RW, Schütte C, von Kleist M, Merigan TC.

PLoS One. 2013 Apr 17;8(4):e61102. doi: 10.1371/journal.pone.0061102. Print 2013.

14.

Update of the drug resistance mutations in HIV-1: March 2013.

Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer RW, Wensing AM, Richman DD.

Top Antivir Med. 2013 Feb-Mar;21(1):6-14. No abstract available. Erratum in: Top Antivir Med. 2013 Apr-May;21(2):46.

15.

HIV-1 fitness landscape models for indinavir treatment pressure using observed evolution in longitudinal sequence data are predictive for treatment failure.

Sangeda RZ, Theys K, Beheydt G, Rhee SY, Deforche K, Vercauteren J, Libin P, Imbrechts S, Grossman Z, Camacho RJ, Van Laethem K, Pironti A, Zazzi M, Sönnerborg A, Incardona F, De Luca A, Torti C, Ruiz L, Van de Vijver DA, Shafer RW, Bruzzone B, Van Wijngaerden E, Vandamme AM; Virolab and EuResist Projects.

Infect Genet Evol. 2013 Oct;19:349-60. doi: 10.1016/j.meegid.2013.03.014. Epub 2013 Mar 21.

16.

Cooperative effects of drug-resistance mutations in the flap region of HIV-1 protease.

Foulkes-Murzycki JE, Rosi C, Kurt Yilmaz N, Shafer RW, Schiffer CA.

ACS Chem Biol. 2013 Mar 15;8(3):513-8. doi: 10.1021/cb3006193. Epub 2012 Dec 27.

17.

Low-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of Lamivudine treatment.

Margeridon-Thermet S, Svarovskaia ES, Babrzadeh F, Martin R, Liu TF, Pacold M, Reuman EC, Holmes SP, Borroto-Esoda K, Shafer RW.

Antimicrob Agents Chemother. 2013 Jan;57(1):343-9. doi: 10.1128/AAC.01601-12. Epub 2012 Oct 31.

18.

Collinearity of protease mutations in HIV-1 samples with high-level protease inhibitor class resistance.

Babrzadeh F, Varghese V, Pacold M, Liu TF, Nyrén P, Schiffer C, Fessel WJ, Shafer RW.

J Antimicrob Chemother. 2013 Feb;68(2):414-8. doi: 10.1093/jac/dks409. Epub 2012 Oct 19.

19.

Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations.

Winters MA, Lloyd RM Jr, Shafer RW, Kozal MJ, Miller MD, Holodniy M.

PLoS One. 2012;7(7):e40514. doi: 10.1371/journal.pone.0040514. Epub 2012 Jul 18.

20.

HIV-1 antiretroviral resistance: scientific principles and clinical applications.

Tang MW, Shafer RW.

Drugs. 2012 Jun 18;72(9):e1-25. doi: 10.2165/11633630-000000000-00000. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk